Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 850 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Benzodiazepine Clear all

Conditions: Oral Sedation and Cervical Dilator Pain
Interventions: Oxycodone and Lorazepam (Active Comparator), Placebo Comparator; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: lorazepam, diphenhydramine hydrochloride, haloperidol, questionnaire administration, laboratory biomarker analysis; Drug · Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Alzheimer Disease
Interventions: Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan), BMS-708163, BMS-708163 + Cooperstown Cocktail; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Hamilton, New Jersey

Conditions: Schizophrenia
Interventions: Clozapine, Olanzapine, Haloperidol; Drug
Lead sponsor: Nathan Kline Institute for Psychiatric Research; Other
Eligibility: 18 Years to 60 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Orangeburg, New York

Conditions: Focal Epilepsy, Generalized Seizure, Drug Refractory Epilepsy
Interventions: UNEEG SubQ device, seizure forecasts, nasal diazepam, Preventative Medication (PM); Device · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions: Sublingual orally disintegrating olanzapine (SODO), Oral olanzapine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Escondido, California • Garden Grove, California • National City, California + 4 more

Conditions: Cocaine Dependence
Interventions: Ketamine, Midazolam; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 60 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Malignant Neoplasm
Interventions: Palonosetron Hydrochloride, Ondansetron Hydrochloride, Dexamethasone, Fosaprepitant Dimeglumine, Olanzapine, Placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 690 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 565
States / cities: Birmingham, Alabama • Fairbanks, Alaska • Kingman, Arizona + 372 more

Conditions: Hyperglycemia, Hyperlipidemia
Interventions: Olanzapine, Ziprasidone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Epilepsy
Interventions: nasal Midazolam; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Alcoholism
Interventions: lorazepam (Ativan), carbamazepine (Tegretol); Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 21 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Advanced Cancer
Interventions: Olanzapine, Placebo; Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Birmingham, Alabama • Indianapolis, Indiana • Rochester, Minnesota + 2 more

Conditions: Bipolar Disorder
Interventions: Olanzapine, Paliperidone ER, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 768 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 16
States / cities: Scottsdale, Arizona • Riverside, California • San Diego, California + 13 more

Conditions: Bipolar Disorder, Major Depressive Episode, Suicidal Ideation
Interventions: Ketamine, Midazolam; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Brain Metastasis
Interventions: Standard of Care FDG-PET Imaging; Procedure
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Weight Gain
Interventions: Olanzapine plus modafinil, Olanzapine plus placebo; Drug
Lead sponsor: Neuropsychiatric Research Institute, Fargo, North Dakota; Other
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy
Interventions: GLPG0634, Midazolam; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 40 Years to 60 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Substance Use Disorders
Interventions: Distress Tolerance - Benzodiazepine Discontinuation (DT-BD), Relaxation Therapy; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania • Wilkinsburg, Pennsylvania

Conditions: Healthy Volunteers
Interventions: Blinded Study Medication - Condition 1, Blinded Study Medication - Condition 2, Blinded Study Medication - Condition 3, Blinded Study Medication - Condition 4, Blinded Study Medication - Condition 5, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lumbar Spine Spondylosis, Anxiety Generalized
Interventions: Midazolam; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Schizophrenia
Interventions: Aripiprazole Once-Monthly, Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc); Drug
Lead sponsor: Matt Byerly; Other
Eligibility: 18 Years to 60 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Refractory Status Epilepticus
Interventions: Perampanel; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK1265744 30 mg oral, Midazolam 3 mg oral + GSK1265744 30mg oral, GSK1265744 400 mg (200 nm), GSK1265744 400 mg (1 micro m), GSK1265744 400 mg (5 micro m); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Bipolar Depression
Interventions: orally-disintegrating olanzapine, regular olanzapine; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Oral Sedation During Cervical Dilator Placement

Lorazepam, Diphenhydramine Hydrochloride, and Haloperidol Gel in Healthy Volunteers

Drug Interaction Study With a Potential Alzheimer's Disease Compound

Clozapine and Olanzapine Treatment of Aggression

Optimizing Therapy in Epilepsy Using Seizure Forecasts Via EEG and Wearables

Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)

The Effect of Brief Potent Glutamatergic Modulation on Cocaine Dependence

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone

Pharmacodynamics of Nasal and Buccal Midazolam Using EEG

Drug Therapy for Alcohol Detoxification

Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients

A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder

Ketamine for Suicidality in Bipolar Depression

Methionine and PBR28-PET (Peripheral Benzodiazepine Receptors) in Brain Metastases Following Radiosurgery

Effects of Modafinil on Olanzapine Weight Gain

A Phase I, Open Interaction Study Between GLPG0634 and Midazolam in Healthy Subjects

Distress Tolerance for Benzodiazepine Discontinuation

Measuring Acute Drug Demand in Humans II

The Effect of Midazolam Sedation on Diagnostic Medial Branch Blocks

Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia

Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus

A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects

Medication, Weight Gain and GI Hormones